Dropless Cataract Surgery: Impact of Initial OMIDRIA® Study Results

Join the study Principal Investigators, Paul Singh, Cathy McCabe, and Brian Shafer, as they discuss preliminary findings from their recent study looking at a dropless postoperative surgery regimen including OMIDRIA vs. a standard topical regimen. Discover how using OMIDRIA as part of a dropless regimen can streamline surgical processes, enhance patient compliance, and reduce the burden of topical drops. Learn how this approach not only improves patient outcomes and satisfaction but also increases operational efficiency within clinics by minimizing the time spent on post-operative eye drop management. Learn why now is the ideal time to incorporate a dropless strategy. You’ll hear the compelling initial data, including information addressing common concerns about patient compliance and inflammation control.

 

This podcast is provided for general information purposes only. The presenters’ views are their own. Nothing contained within this podcast is intended to offer medical advice for the treatment of any illness or disease. Please use clinical judgment when considering treatment. Refer to Rayner product labeling and instructions for use. A dropless approach with OMIDRIA may not suit all patients. Rayner does not recommend specific product combinations. As of March 2025, OMIDRIA is approved in the US and UK. Speakers may be paid Rayner consultants. Rayner®, the Rayner logo, OMIDRIA, and the OMIDRIA logo, are proprietary marks of Rayner. © 2025 Rayner Group, all rights reserved. OMIDRIA podcasts are for the attention of US HCPs only. US-OM-2500001 03/25